Non-Operative Treatment for CRC May Include Observation After Complete Response
CHICAGO -- Patients who skipped maintenance therapy after a complete response to upfront treatment with a PD-1 inhibitor lived just ...
Tenecteplase Unseats Low-Dose Alteplase Favored for Asian Patients
T-FLAVOR investigators compared tenecteplase with low-dose alteplase in stroke patients scheduled for endovascular therapy (EVT).The trial notably took place in ...
Emma Barnett: Fighting Endometriosis
Emma Barnett exposes the devastating reality of endometriosis and its toll on women. Source link : https://www.bbc.co.uk/iplayer/episode/m002x8nb?at_medium=RSS&at_campaign=rss Author : Publish ...
Obesity With a Normal BMI? Study Suggests It’s Common
Over 26% of U.S. adults with a normal BMI met new criteria for clinical obesity proposed by the Lancet commission.About ...
Patients With Tardive Dyskinesia Symptoms May Go Undiagnosed
Tardive dyskinesia (TD), a movement disorder that causes involuntary movements often triggered by antipsychotic exposure, has appeared in the DSM ...
FDA Approves Cefepime-Zidebactam for Complicated UTIs
The novel IV antibiotic combination works ‘synergistically’ to combat gram-negative pathogens in complicated UTIs and pyelonephritis. Medscape Medical News Source ...
AI Spots Undertreated Heart Failure Risk Early
An AI tool applied to NHS health records identified stable-appearing heart failure patients who were undertreated and at high risk ...
Targeted Combo Boosts PFS in BRAF-Mutant Metastatic Colorectal Cancer
CHICAGO -- Adding encorafenib (Braftovi) and cetuximab (Erbitux) to FOLFIRI chemotherapy significantly improved progression-free survival (PFS) as first-line treatment of ...
CELMoD Drug Cuts Risk of Myeloma Progression, Death by 52% in Trial
CHICAGO -- Adding a novel cereblon E3 ligase modulation (CELMoD) drug to a standard multiple myeloma regimen significantly improved progression-free ...
Discussing Emerging Therapies and Shared Decision-Making in Multiple Myeloma
Developed in partnership with the Our Partner In "Beyond Diagnosis: Multiple Myeloma," Cleveland Clinic hematologist Sandra Mazzoni, DO, and host ...
‘Transformative’ pancreatic cancer drug doubles survival time
The drug daraxonrasib is being put forward to treat people with advanced pancreatic cancer in clinicsREUTERS/Danielle Villasana A daily pill ...
FDA Approves Oral Antiviral to Prevent COVID-19 After Exposure
The FDA approved the oral antiviral agent ensitrelvir (Xocova) to help prevent COVID-19 in people ages 12 years or older ...
Saroglitazar Boosts Response Rates in Primary Biliary Cholangitis
Novel saroglitazar significantly improved biochemical response rates in patients with primary biliary cholangitis (PBC) who had an inadequate response to ...
‘I’ve requested a full hysterectomy’
Emma Barnett shares her life-long struggle with endometriosis – a disease affecting one in ten women of reproductive age, which ...
U.S. Adult Cigarette Smoking Rate Hits Another All-Time Low
The cigarette smoking rate among U.S. adults dropped to another all-time low last year, with one in 11 adults saying ...
The Pro-Life Movement’s Cruelty Problem
She stays quiet because of her child, my patient tells me. But despite her passivity, her husband always manages to ...
Do turmeric and curcumin have any actual health benefits?
A compound in turmeric called curcumin is sold in supplement form, but what are its benefits?SOLDATOOFF/Shutterstock As the temperature drops ...
Albumin 5% Cut Mortality Rates in Sudden Liver Failure With Other Organ Failure
Plasma exchange with albumin 5% (Albutein 5%, PE-A5%) added to standard medical treatment (SMT) improved outcomes in patients with acute-on-chronic ...
Risk of Tardive Dyskinesia Higher in Women
Patients taking antidopaminergic agents are at risk of developing tardive dyskinesia (TD), a disorder characterized by abnormal, involuntary movements of ...
How human error became a weapon against large language models
Typos are a sign of a human writer… for nowMarc De Simone/Alamy Recently, a friend told me over coffee about ...
